NASDAQ:TNXP Tonix Pharmaceuticals Q1 2026 Earnings Results & Report $6.40 +0.27 (+4.40%) Closing price 04:00 PM EasternExtended Trading$6.37 -0.03 (-0.45%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Tonix Pharmaceuticals missed analyst earnings expectations but beat on revenue in its Q1 2026 results, released May 11, 2026. The company reported EPS of -$2.93 versus the -$2.54 consensus estimate, while revenue of $6.88 million topped the $6.13 million estimate by $0.75 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 11, 2026TimeBefore Market OpensConference Call7:00 AM ET Tonix Pharmaceuticals EPS ResultsActual EPS-$2.93Consensus EPS -$2.54Beat/MissMissed by -$0.39One Year Ago EPSN/AEPS Beat Rate2 of last 7 quartersTonix Pharmaceuticals Revenue ResultsActual Revenue$6.88 millionExpected Revenue$6.13 millionBeat/MissBeat by +$753.00 thousandYoY Revenue GrowthN/AUpcoming EarningsTonix Pharmaceuticals' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Tonix Pharmaceuticals Q1 2026 Earnings FAQ Did Tonix Pharmaceuticals beat earnings estimates for Q1 2026? Tonix Pharmaceuticals (NASDAQ:TNXP) reported earnings of -$2.93 per share for Q1 2026, missing the consensus estimate of -$2.54. The report was announced on Monday, May 11, 2026. What was Tonix Pharmaceuticals' revenue for Q1 2026? Tonix Pharmaceuticals reported revenue of $6.88 million for Q1 2026, against a consensus estimate of $6.13 million. When is Tonix Pharmaceuticals' next earnings date? Tonix Pharmaceuticals' next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for Tonix Pharmaceuticals on the company's earnings history page. Tonix Pharmaceuticals Earnings HeadlinesTonix Pharmaceuticals (NASDAQ:TNXP) vs. SAB Biotherapeutics (NASDAQ:SABS) Head to Head ReviewOctober 12 at 7:44 AM | americanbankingnews.comAnalyzing Tonix Pharmaceuticals (NASDAQ:TNXP) and WAVE Life Sciences (NASDAQ:WVE)October 7, 2026 | americanbankingnews.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.October 14 at 1:00 AM | Awesomely (Ad)Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded at Wall Street ZenOctober 4, 2026 | americanbankingnews.comTonix Pharmaceuticals Holding Corp (TNXP)September 23, 2026 | in.investing.comTonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®September 22, 2026 | finance.yahoo.comSee More Tonix Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tonix Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tonix Pharmaceuticals and other key companies, straight to your email. Email Address About Tonix PharmaceuticalsTonix Pharmaceuticals (NASDAQ:TNXP) is a clinical-stage biopharmaceutical company focused on developing medicines and vaccines for conditions involving the central nervous system, immunology, and infectious diseases. The company combines small-molecule drugs, biologics, and vaccine platforms in its research and development programs. Tonix’s pipeline has included TNX-102 SL, a sublingual formulation of cyclobenzaprine investigated for the management of fibromyalgia and other pain-related conditions. The company has also pursued therapies based on intranasal oxytocin for conditions such as obesity and neurodevelopmental disorders, as well as vaccine candidates intended to address diseases including smallpox, mpox, and COVID-19. Tonix Pharmaceuticals was founded in 2007 and is headquartered in Chatham, New Jersey. The company’s programs are primarily developed through research, clinical testing, and collaborations, with potential applications in the United States and international markets. Seth Lederman, M.D., is the company’s founder, chairman, and chief executive officer.View Tonix Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
